Tests ADX-038 in adults with complement-mediated kidney disease
Tests ADX-038 in adults with kidney diseases driven by the complement system.
Plain-language title generated from the registry record
Registry title: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Key facts
- Where
- Columbus, Dakota Dunes, Dallas, Doral, Great Neck, Houston, Iowa City, Miami, Pembroke Pines, Shelby, and Shreveport, United StatesSee the 11 sites
- Phase
- Phase 2
Where in United States
- ColumbusColumbus, United StatesTaking people
- Dakota DunesDakota Dunes, United StatesTaking people
- DallasDallas, United StatesNo longer taking part
- DoralDoral, United StatesNo longer taking part
- Great NeckGreat Neck, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Iowa CityIowa City, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Pembroke PinesPembroke Pines, United StatesNo longer taking part
- ShelbyShelby, United StatesTaking people
- ShreveportShreveport, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ADARx Pharmaceuticals, Inc.
- Trial code
- NCT06989359
- Record updated
- 20 October 2026
- Original description
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.Read full original descriptionShow less
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Inclusion: Mean eGFR greater than or equal to 30 mL/min/1.73m2; Clinical evidence of active kidney disease; Treated with supportive care including an ACE inhibitor or ARB if applicable; Willing to receive required vaccinations; Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy.
Exclusion: Kidney transplant or renal replacement therapy; Received complement inhibitor treatments; History of solid organ transplant; Other kidney disease; History of recurrent invasive infections; Active systemic viral, bacterial, or fungal infection; Hereditary or acquired complement deficiency; Abnormal liver function.